who we are
Making Hearing A Priority
Cilcare is a biotech dedicated to harnessing auditory sciences to reshape the future of care via early diagnosis and targeted treatment. We believe hearing acts as a valuable indicator of our health and must be monitored and preserved accordingly. As awareness of the link between hearing and chronic health conditions grows, auditory sciences are paving the way for the early detection of chronic neurocognitive, inflammatory, and age-related diseases.
We firmly believe uniting auditory sciences and Artificial Intelligence elevates clinical research, allowing patients to receive the proper treatment at the right time. This synergy also heralds a revolution in a new pillar of precision medicine.
We believe that scientific excellence and experience are fundamental to R&D in neurosciences & otology. Progress and success thrive when passionate, ambitious, and resilient experts work toward a common goal with stakeholders, sharing collective intelligence.
Our mission is to ensure hearing impairments are addressed earlier and with precision, as they are often associated with chronic diseases from their very early stages.
Cilcare was founded in 2014 by 3 women: scientists and business executives with large backgrounds in the pharmaceutical industry. Cilcare’s initial mission was fueled by the ambition to offer solutions to millions of individuals suffering from ear diseases, an area marked by significant unmet medical needs.
Cilcare’s approach revolves around providing a crucial missing element in the drug development process, specifically addressing the translational research stage. Cilcare set up a cutting-edge R&D platform, with robust and translational pharmacological models of noise-induced hearing loss, synaptopathy, drug-induced ototoxicity, tinnitus, and otitis.
In 2017, Cilcare partnered with CBSET, a translational biomedical center linked to the MIT, to accelerate its mission and development in the United States and expand its external innovation platform to include GLP-compliant ototoxicity studies, gene and cell therapies.
In less than a decade, Cilcare has emerged as a catalyzer in drug, medical devices, gene and cell therapy development for hearing loss and tinnitus, driving transformative breakthroughs. Cilcare’s collaborations with leading hearing research companies and academic institutions across the globe have resulted in track records of over 100 deals and a network of over 3,000 qualified potential business partners. Cilcare’s scientific excellence has been recognized by major Key Opinion Leaders, with some of the best having joined its Scientific Advisory Board.
In 2020, using an unmatched understanding of the physiopathology of inner ear disorders and therapeutic targets, Cilcare conducted a comprehensive assessment to identify compounds ideally positioned for hearing diseases. As a result, Cilcare successfully acquired four compounds from a big pharmaceutical company’s R&D portfolio, specifically tailored to address cochlear synaptopathy and other forms of auditory disorders.
In 2023, Cilcare launched a first observational clinical trial in diabetic patients aiming to deepen knowledge of the link between diabetes and hearing pathologies. Clinical results will help define novel auditory biomarkers in neuro-inflammatory diseases and optimize patient recruitment in clinical studies.
Hearing plays an indispensable role in the human experience, serving as a cornerstone for various aspects of life. It underpins communication, facilitates learning, fosters social interaction, enables emotional expression, and ensures safety. Cilcare is dedicated to harnessing auditory sciences to drive medical innovation to improve patient care. These guidelines are led by inner values shared by all its team members and are the source of our motivation:
Cilcare is ISO 9001:2015 certified.